GMED or AXGN: Which Is the Better Value Stock Right Now?
GMED vs. AXGN: Which Stock Is the Better Value Option?
Zacks
GMED or AXGN: Which Is the Better Value Stock Right Now?
GMED vs. AXGN: Which Stock Is the Better Value Option?
Zacks
More News
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Kscore Test.
Zacks
Reasons to Add STE Stock to Your Portfolio Right Now
STERIS' strong Healthcare growth, improving AST prospects and rising Life Sciences demand bolster its outlook, despite tariff and inflationary pressures.
Zacks
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.
Zacks
Is it Apt to Retain Medtronic Stock in Your Portfolio Now?
MDT expands in cardiac ablation, robotics, hypertension and digital surgery, but tariff, inflation and currency risks are likely to pressure margins.
Zacks
BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients
BDX's Revello stent shows strong nine-month AGILITY trial results, with high vessel patency and low failure rates, boosting its peripheral vascular prospects.
Zacks
Doximity Deepens U.S. News Alliance to Improve Patient Access to Care
DOCS extends its 13-year partnership with U.S. News, strengthening its role in physician searches, appointment booking and hospital rankings.
Zacks
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?
PBH's brand-building, acquisitions and e-commerce growth support fiscal 2027 revenue gains, but competition and currency risks remain key challenges.
Zacks
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's MedSurg growth and NexSys PCS adoption support its prospects, but competitive pressures and unfavorable currency movements pose risks.
Zacks
West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?
West Pharmaceutical shares have surged 36.1% YTD, fueled by strong demand for high-value components, earnings momentum and raised guidance. Can the rally continue?